Alphatec (ATEC) Stock May Trade Below Fair Value On Sales Growth

Alphatec Holdings stock has fallen 54.1% year to date, yet the latest valuation checks suggest the shares may now be pricing in a lot of that weakness. The key issue for investors is whether the recent rebound hints at a market starting to reassess that view.

• The stock is down 54.1% year to date, which points to a sharp reset in expectations already reflected in the price.
• Future growth in spinal surgery volumes can support sentiment, while any setback in execution or higher funding needs may weigh heavily on what investors are willing to pay.
• The company screens as undervalued in 5 out of 6 valuation checks, so the broader indicators currently lean toward the shares looking cheap.

The stock's next move may depend on whether Alphatec Holdings can justify those supportive valuation signals with business performance that the market is prepared to reward.

Find out why Alphatec Holdings' -30.9% return over the last year is lagging behind its peers.

Is Alphatec Holdings a Bargain on Sales?

The P/S ratio tends to suit Alphatec Holdings because revenue is a cleaner yardstick than earnings for a company with losses and heavy investment.

Right now Alphatec Holdings trades on a P/S of about 1.9x. That sits below the Medical Equipment industry average of roughly 2.9x and also below the peer group average near 4.8x. On a simple comparison, investors are paying less for each dollar of Alphatec Holdings revenue than for many similar stocks in the sector.

The tailored fair P/S ratio for Alphatec Holdings is estimated at about 3.4x. This incorporates factors such as the company’s size, risks and the quality of its revenue rather than just a blunt industry average. The current 1.9x multiple is well under that fair level, which indicates the market is pricing the stock at a discount to what this framework implies for the business.

On the P/S multiple, Alphatec Holdings stock currently appears undervalued relative to both the industry and its own modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Alphatec Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Alphatec Holdings link the valuation puzzle above with specific assumptions the market might be making about Alphatec Holdings' future growth, margins and earnings, and they sit on the company’s Community page. Each one ties its number to a clear view on how growth, profitability and risks could develop, which you can revisit as new information and results come through.

One of the top community narratives on Alphatec Holdings: 40% undervalued

"Expanding surgeon adoption, strong same-store sales growth, and increasing procedural volume signal Alphatec's ability to leverage the aging population and rising prevalence of spinal conditions..."

Read one of the top narratives on Alphatec Holdings

Do you think there's more to the story for Alphatec Holdings? Head over to our Community to see what others are saying!

The Bottom Line

For Alphatec Holdings, the current market-multiple work points to the stock trading on an undervalued footing relative to peers and its own tailored fair P/S ratio. That discount will only close if the company can deliver business performance that keeps revenue quality and growth expectations intact while managing funding needs. The real debate is whether the lower multiple reflects temporary caution or a lasting concern about execution and capital demands. What matters most from here is how convincingly Alphatec Holdings converts its spinal surgery opportunity into durable, scalable revenue without eroding investor confidence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com